Program
zalifrelimab
Also written as “Zalifrelimab”, “UGN-301” and “Balstilimab + Zalifrelimab”.
Its studies are mostly in Uterine Cervical Neoplasms · Prostatic Neoplasms · Non-Muscle Invasive Bladder Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Agenus | 40 open or running | phase 2since Feb 12, 2016 | Feb 12, 2016 | none ahead |
| ImmunoGenesis | 11 open or running | phase 2since Jan 9, 2025 | Jan 9, 2025 | Oct 2027phase 2 · NCT06782555 |
| UroGen Pharma | 10 open or running | phase 1since May 5, 2022 | May 5, 2022 | none ahead |
Also a collaborator on its studies: Betta Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 12, 2016First study: phase 2 study in Advanced Solid CancersNew to AgenusAgenus · NCT02694822 · 89 enrolled · United States
- Nov 14, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungAgenus · NCT03411473 · 2 enrolled · Australia, New Zealand
- Jan 19, 2018Phase 2 study in Uterine Cervical NeoplasmsAgenus · NCT03495882 · 175 enrolled · United States, Australia, Brazil and more
- Aug 27, 2021Phase 2 study in Uterine Cervical NeoplasmsAgenus · NCT05033132 · China
- May 5, 2022UroGen Pharma's first study: phase 1 study in Non-Muscle Invasive Bladder NeoplasmsNew to UroGen PharmaUroGen Pharma · NCT05375903 · 51 enrolled · United States, Italy, Spain
- Jan 9, 2025ImmunoGenesis's first study: phase 2 study in Prostatic NeoplasmsNew to ImmunoGenesisImmunoGenesis · NCT06782555 · 71 enrolled · United States
Ahead
- Oct 2027Primary completion: phase 2 study in Prostatic NeoplasmsImmunoGenesis · NCT06782555
TargetBeta
“A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities”NCIt, by rule
“Cytotoxic T-lymphocyte protein 4 inhibitor”ChEMBL 37, by rule
Other programs on CTLA4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tremelimumabrule | AstraZeneca | phase 3 | 47 |
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| Anti-CTLA-4 Monoclonal Antibody SHR-8068rule | Jiangsu HengRui Medicine | phase 3 | 16 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-CTLA-4 Monoclonal Antibody IBI310rule | Innovent Biologics | phase 3 | 11 |
| gotistobartrule | oncoc4-inc | phase 3 | 5 |
| porustobartrule | harbour-biomed-guangzhou-co-ltd | phase 2 | 5 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| GB268rule | eddingpharm-zhuhai-co-ltd | phase 2 | 2 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06782555Prostatic Neoplasms · United States | 2 | Active, not recruiting | ImmunoGenesis | Oct 2027 | 71 |
| NCT05375903Non-Muscle Invasive Bladder Neoplasms · United States, Italy, Spain | 1 | Completed | UroGen Pharma | Jan 9, 2026 | 51 |
| NCT05033132Uterine Cervical Neoplasms · China | 2 | Withdrawn | Agenus | Dec 30, 2024 | 0 |
| NCT03495882Uterine Cervical Neoplasms · United States, Australia, Brazil and more | 2 | Completed | Agenus | Jul 15, 2022 | 175 |
| NCT03411473Carcinoma, Non-Small-Cell Lung · Australia, New Zealand | 2 | Terminated | Agenus | May 1, 2018 | 2 |
| NCT02694822Advanced Solid Cancers · United States | 2 | Completed | Agenus | Mar 30, 2022 | 89 |
How it is read
Names in the registry
- “Zalifrelimab”, 3 entries
- “UGN-301”, 1 entry
- “Balstilimab + Zalifrelimab”, 1 entry
- “AGEN1884 in combination with pembrolizumab”, 1 entry
Conditions, from the studies’ own filings
- Uterine Cervical Neoplasms, 2 studies
- Prostatic Neoplasms, 1 study
- Non-Muscle Invasive Bladder Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.